Skip to search formSkip to main contentSkip to account menu

Synthetic Lethality

Known as: Lethality, Synthetic 
National Institutes of Health

Related topics

Related topics

1 relation
Synthetic Lethal Mutations

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Harnessing DNA Double-Strand Break Repair for Cancer Treatment
DNA double-strand breaks (DSBs) are highly deleterious, with a single unrepaired DSB being sufficient to trigger cell death… 
2019
2019
AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress
Translesion DNA synthesis (TLS) and homologous recombination (HR) cooperate during S-phase to safeguard replication forks… 
Review
2017
Review
2017
Targeting DNA repair and replication stress in the treatment of ovarian cancer
Approximately half of high-grade serous epithelial ovarian cancers incur alterations in genes of homologous recombination (BRCA1… 
Review
2017
Review
2017
Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Highly Cited
2016
Highly Cited
2016
Synthetic lethality between PAXX and XLF in mammalian development
Balmus et al. report that Paxx/Xlf double-knockout mice display embryonic lethality associated with genomic instability, cell… 
2016
2016
Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations
The components of the Switch/Sucrose non-fermentable (SWI/SNF) complex are mutated in approximately 20% of human cancers. The A/T… 
Review
2016
Review
2016
New treatment option for ovarian cancer: PARP inhibitors
Poly(ADP-ribose) polymerase (PARP), which was first described over 50 years ago by Mandel, are a family of protein enzymes… 
Highly Cited
2015
Highly Cited
2015
Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
Human lung adenocarcinomas (LUAD) contain mutations in EGFR in ∼15% of cases and in KRAS in ∼30%, yet no individual… 
Highly Cited
2015
Highly Cited
2015
Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
Oncogenic KRas mutations are present in about 30% of all human cancers and in more than 90% of pancreatic cancers. KRas-driven… 
Highly Cited
2015
Highly Cited
2015
Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)